Pubmed logo


  1. Villa, NY, Franco, LS and McFadden, G. Ex vivo virotherapy with myxoma virus to treat cancer. "Oncolytic Viruses: Methods and Protocols", in the series "Methods in Molecular Biology" 2958: 95-110. Springer Nature Press. (2020).

  2. Rahman, MM and G McFadden. Oncolytic virotherapy with myxoma virus. J Clin Med. 9: 171 (2020).

  3. De Matos, AL*, Franco, LS* and G McFadden (*co-lead authors). Oncolytic viruses and the immune system: The dynamic duo. Mol Therapy-Methods & Clinical Development 17: 349-358 (2020).

  4. Rodrigues, TCS, Subramaniam, K, Varsani, A, McFadden, G, Schaefer, AM, Bossart, GD, Romero, CH and TB Waltzek. Genome characterization of cetaceanpox virus from a managed Indo-Pacific bottlenose dolphin (Tursiops aduncus). Virus Research 278: 197861 (2020).

  5. McFadden, G. Passing the torch. PLoS Pathogens 16 (1): e1008306. (2020).

  6. Rahman, MM and G McFadden. Myxoma virus-encoded host range protein M029: A multifunctional antagonist targeting multiple host antiviral and innate immune pathways. Vaccines 8: 244 (2020).

  7. Hadrys, A, Sochanik, A, McFadden, G and J Jazowiecka-Rakus. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses. Eur J Pharmacology 874: 172991 (2020).

  8. Villa, NY, Rahman, MM, Mamola, J, D’Isabella, J, Goras, E, Kilbourne, J, Lowe, K, Daggett-Vondras, J, Torres, L, Christie, J, Appel, N, Cox, AL, Kim, JB, and G McFadden. Autologous transplantation using donor leukocytes loaded ex vivo with oncolytic myxoma virus can eliminate residual multiple myeloma. Molecular Therapy-Oncolytics (2020, in press).


  1. Van Vloten, JP, Santry, LA, McAusland, TM, Karimi, K, McFadden, G, Petrik, JJ, Wootton, SK and Bridle, BW. Quantifying antigen-specific T-cell responses when using antigen-agnostic immunotherapies. Molecular Therapy-Methods & Clinical Development 13: 154-166 (2019).

  2. Van Vloten, JP, Klafuric, EM, Karimi, K, McFadden, G, Petrik, JJ, Wootton, SK and Bridle, BW. Quantifying antibody responses induced by antigen-agnostic immunotherapies. Molecular Therapy-Methods & Clinical Development 14: 189-196 (2019).

  3. Tang, B, Schane, C, Yan, D, Guo, ZS, Bartlett, DL, Liu, J, McFadden, G, Grosenbach, D, Shisler, JL and Roy, EJ. A cautionary note on the selectivity of oncolytic viruses. Oncolytic Virotherapy 8: 3-8 (2019).

  4. Alves, JM, Carneiro, M, Cheng, JY, Lemos de Matos, A, Rahman, MM, Loog, L, Campos, PF, Wales, N, Eriksson, A, Manica, A, Strive, T, Graham, SC, Afonso, S, Bell, DJ, Day, JP, Fuller, SJ, Marchandeau, S, Palmer, WJ, Queney, G, Surridge, AK, Vieira, FG, McFadden, G, Nielsen, R, Gilbert, MTP, Esteves, PJ, Ferrand, N, and Jiggins, FM. Parallel adaptation of rabbit populations to myxoma virus. Science 363: 1319-1326 (2019).

  5. Garg, R, Jackson, C, Rahman, MM, Khan, AR, Lewin, AS and McFadden, G. Myxoma virus M013 protein antagonizes NF-kB and inflammasome pathways via distinct structural motifs. J Biol. Chemistry 294(21): 8480-8489 (2019).

  6. Shabashvili, D, Kellish, P, Rahman, MM, Nawab, A, Guijarro, MV, Zhang, M, Cao, C, Moussatche, N, Reinhard, M, Jantz, M, Mehta, HJ, McFadden, G, Kaye, FJ, and Zajac-Kaye, M. Oncolytic myxoma virotherapy for small cell lung cancer induces immune cell infiltration and prolongs survival. J Clinical Investigation 129(6): 2279-2292 (2019).

  7. Torres-Dominguez, LE and McFadden, G. Poxvirus oncolytic virotherapy. Expert Opinion Biol Therapies 6: 561-573 (2019).

  8. Zhang, L, Yaron, JR, Tafoya, AM, Wallace, SE, Kilbourne, J, Haydel, S, Rege, K, McFadden, G, and AR Lucas. A virus-derived immune modulating serpin accelerates wound closure with improved collagen remodeling. J Clinical Medicine 8(10) E1626 (2019).

  9. Yaron, JR, Kwiecien, JM, Zhang, L, Ambadapadi, S, Wakefield, DN, Clapp, WL, Dabrowski, W, Burgin, M, Munk, BH, McFadden, G, Chen, H, and AR Lucas. Modifying the organ matrix pre-engraftment: A new transplant paradigm? Trends Mol Medicine 7: 626-639 (2019).

  10. Agueda-Pinto, A, Lemos de Matos, A, Abrantes, M, Kraberger, S, Risalde, MA, Gortazar, C, McFadden, G, Varsani, A and Esteves, PJ. Genetic characterization of a recombinant myxoma virus leap into the Iberian hare (Lepus granatensis). Viruses 11: 530; BioRxiv: (2019).


  1. Rahman, MM, Bagdassarian, E, Ali, MAM, and McFadden, G. Identification of host DEAD-box helicases that regulate cellular tropism of oncolytic myxoma virus in human cancer cells. Scientific Reports, 7: 15710 (2018).

  2. Esteves, PJ, Abrantes, J, Baldauf, HM, BenMohamed, L, Chen, Y, Christensen, N, González-Gallego, J, Giacani, L, Hu, J, Kaplan, G, Keppler, OT, Knight, KL, Kong, XP, Lanning, DK, Pendu, J, Lemos de Matos, A, Liu, J, Liu, S, Lopes, AM, Lu, S, Lukehart, S, Manabe, YC, Neves, F, McFadden, G, Pan, R, Peng, X, de Sousa-Pereira, P, Pinheiro, A, Rahman, MM, Ruvoën-Clouet, N, Subbian, S, Tuñón, MJ, van der Loo, W, Vaine, M, Via, L, Wang S, and Mage, R. The wide utility of rabbits as models of human diseases. Experimental and Molecular Medicine (2018).

  3. Forbes, NS, Coffin, R, Deng, L, Evgin, L, Fiering, S, Giacalone, M, Gravekamp, C, Gulley, JL, Gunn, H, He, M, Hoffman, RM, Kaur, B, Liu, K, Lyerly, K, Marciscano, AE, Moradian, E, Rasooly, A, Ruppel, S, Saltzman, DA, Tattersall, PJ, Thorne, S, Vile, RG,  Zhang, HH, Zhou, S, and McFadden, G. White Paper on Microbial Anti-Cancer Therapy and Prevention. Journal for Immunotherapy of Cancer 6: 78 (2018).

  4. Phelps, MP, Yang, H, Patel, S, Rahman, MM, McFadden, G and Chen, E. Oncolytic virus-mediated RAS targeting in rhabdomyosarcoma. Molecular Therapy-Oncolytics 11:52-61 (2018).

  5. Villa, NY and McFadden, G. Virotherapy as adjunct therapy for Graft-vs-Host Disease. Current Pathobiology Reports 6: 247–263 (2018).

  6. Wolfe, AM, Rahman, M, McFadden, G and Bartee, E. Refinement and successful implementation of a scoring system for myxomatosis in a susceptible rabbit (Oryctolagus cuniculis) model. Comp. Med 68(4): 280-285 (2018).

  7. Lucas A, Yaron J, Zhang L, Macaulay C, McFadden G. Chapter 17. Serpins; Development for Therapeutic Applications. (Editor A Lucas) Serpins, Methods in Molecular Biology, Springer Nature Press, (2018).

  8. Mahon, BP, Ambadapadi S, Yaron, JR, Lomelino CL, Pinard, M, Keinan, S, Kurnikov, I, Macaulay C, Zhang, L, Reeves, W, McFadden G, Tibbetts, S, McKenna R, and Lucas AR. Crystal structure of cleaved Serp-1, a Myxomavirus-derived immune modulating serpin: Structural design of serpin reactive center loop peptides with improved therapeutic function. Biochemistry 57(7): 1096-1107 (2018).


  1. Lilly, CL, Villa, NY, de Matos, AL, Ali, HM, Dhillon, JKS, Hofland, T, Rahman, MM, Chan, W, Bogen, B, Cogle C and McFadden, G. Ex vivo oncolytic virotherapy with myxoma virus arms multiple allogeneic bone marrow transplant leukocytes to enhance graft-vs-tumor. Molecular Therapy-Oncolytics 4: 31-40 (2017).

  2. Rahman, MM and McFadden, G. Species specific inhibition of type I interferon responses by the dsRNA-binding protein M029 regulates myxoma virus cell species tropism independently of PKR. Viruses 9(2):27 (2017).


  1. McFadden, G. Speaking of Medicine Community Blog: Reflections from Haiti-2016. PLoS Medicine, Pathogens, Neglected Tropical Diseases Blogs (2016):

  2. Andrade, LG, Albarnaz, JD, Mugge, FLB, David, BA, Abrahao, JS, Fonseca, FG, Kroon, EG, Menezes, GB, McFadden, G and Bonjardim, CA. Vaccinia virus dissemination requires p21-activated kinase 1. Archives Virology DOI 10.1007/s00705-016-2996-3 (2016).

  3. Villa, NY, Rahman, MM, McFadden, G and Cogle, CR. Therapeutics for Graft-vs-Host-Disease: From conventional therapies to novel virotherapeutic strategies. Viruses 8:85; doi:10.3390/v8030085 (2016).

  4. Peng, C, Haller, S, Rahman, MM, McFadden, G and Rothenberg, S. Myxoma virus M156 is a specific inhibitor of rabbit PKR and contains a loss-of-function mutation in Australian virus isolates. PNAS doi: 10.1073/pnas.1515613113 (2016).

  5. Pisklakova, A, McKenzie, B, Zemp, F, Lun, X, Etame, A, Kenchappa, RS, Rahman, MR, Reilly, K, Pilon-Thomas, S, McFadden, G, Kurz, E and Forsyth, P. M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma. Neuro-Oncology doi:10.1093/neuonc/now006 (2016).

  6. Villa, N, Bais, S, Meachem, AM, Wise, E, Rahman, MM, Moreb, J, Rosenau, EH, Wingard, JR, McFadden, G and Cogle, CR. Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells Cytotherapy (In press, 2016).

  7. Lucas, A, Wakefield, D, Bryant, M, Chen, H, Ambadapadi, S, Morshed, S, DeJesus, D, Clapp, W and McFadden, G. Glycosaminoglycans (GAGs) in Cardiovascular Disease: Searching for the Sweet Spot. J Clin. Exp. Cardiology 7(1): 1000e141 (2016).


  1. Tong, JG, Valdes, YR, Barrett, JW, Bell, JC, Stojdl, D, McFadden, G, McCart, A, DiMattia, GE and Shepherd, TG. Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. Molecular Therapy-Oncolytics 2: e15013 (2015).

  2. Villa, NY, Wasserfall, C, Meachem, A, Wise, E, Chan, W, Wingard, JR, McFadden, G and Cogle, CR. Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood 125 (24): 3778-3788 (2015).

  3. Kim, M, Rahman, MM, Cogle, CR and McFadden, G. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. Biochemical and Biophysical Research Communications 462: 283-287 (2015).

  4. McFadden, G. The curious road from basic pathogen research to clinical translation. PLoS Pathogens DOI: 10:1371/journal.ppat.1004997 (2015).

  5. McFadden, G and Haldar, K. Introducing “Research Matters”. PLoS Pathogens DOI: 10:1371/journal.ppat.1005014 (2015).

  6. Boutard, B, Vankerckove, S, Markine-Goriaynoff, N, Sarlet, M, Desmecht, D, McFadden, G, Vanderplasschen, A and Gillet, L. The alpha-2,3-sialyltransferase encoded by myxoma virus is a virulence factor that interferes with inflammation. PLoS One 10(2): e011806 (2015).

  7. Ildefonso, CJ, Jaime, H, Rahman, MR, Li, Q, Boye, SE, Hauswirth, WW, Lucas, AR, McFadden, G, and Lewin, AS. AAV vector expressing a virus-derived dual inhibitor of inflammasomes and NF-kB is a novel therapeutic for inflammatory eye disease. Human Gene Therapy 26: 59-68 (2015).

  8. Zemp, FJ, McKenzie, BA, Lun, X, Reilly, KM, McFadden, G, Yong, VW and Forysth, PA. Cellular factors resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Research 74(24): 7260-7273 (2015).

  9. Liu, J and McFadden, G. SAMD9 is an innate antiviral host factor with stress response properties than can be antagonized by poxviruses. J Virology 89(3): 1925-1931 (2015).


  1. Davids, JA, Dai, E, Chen, H, Bartee, MY, Liu, L, Fortunel, A, Moyer, R, McFadden, G and Lucas, AR. Viral anti-inflammatory proteins target diverging immune pathways with converging effects on arterial dilatations, plaque and apoptosis. European J of Inflammation, 12(1): 131-145 (2014).

  2. Tosic, V, Thomas, DL, Kranz, DM, Liu, J, McFadden, G, MacNeil, AL and Roy, EJ. Myxoma virus expressing a fusion protein of Interleukin-15 (IL-15) and IL-15 Receptor alpha has enhanced antitumor activity. PLoS One 9(10): e109801 (2014).

  3. Lamb, SA, Rahman, MM and McFadden, G. Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulence. Virology 464-465: 134-145 (2014).

  4. Chan, W and McFadden, G. Oncolytic poxviruses. Ann. Rev. Virology 1: 191-214 (2014).

  5. Brahn, E, Lee, S, Lucas, A, McFadden, G and Macaulay, C. Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus. Clinical Immunology 153: 254-263 (2014).

  6. Damon, I, Damaso, CR and McFadden, G. Are we there yet? The smallpox research agenda using live variola virus. PLoS Pathogens 10(5): e1004108 (2014).

  7. Weng, M, Gong, W, Ma, M, Chu, B, Qing, Y, Zhang, M, Lun, X, McFadden, G, Forsyth, P, Yang, Y, and Quan, Z. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluron in vivo. Molecular Cancer 13: 82- 97 (2014).

  8. Bell, J and McFadden, G. Viruses for tumor therapy. Cell Host & Microbe 15: 260-265 (2014).

  9. De Matos, AL, McFadden, G and Esteves, PJ. Evolution of viral sensing RIG-I-like receptor genes in Leporidae genera Oryctolagus, Sylvilagus and Lepus. Immunogenetics 66: 43-52 (2014). DOI: 10.1007/s00251-013-0740-7

  10. Haller, SL, Peng, C, McFadden, G and Rothenberg, S. Poxviruses and the evolution of host range and virulence. Infection, Genetics and Evolution 21: 15-40 (2014).


  1. Zheng, D, Chen, H, Martee, MY, Williams, J, Davids, J, Lomas, DA, McFadden, G and Lucas, AR. Myxomaviral anti-inflammatory serpin reduces myeloid-derived suppressor cells and human pancreatic cancer cell growth in mice. J. Cancer Sci Ther 5: 291-299, DOI: 10.4172/1948-5956.1000219 (2013).

  2. Liu, L, Dai, E, Kidwai, B, Davids, J, Macaulay, C, McFadden, G and Lucas, A. Comparative analysis of plaque growth after arterial stent implant with anti-inflammatory chemokine and serine protease inhibitors treatment. J Clinical Experimental Cardiology 4:274, DOI: 10.4172/2155-9880.1000274 (2013).

  3. Hao Chen, Donghang Zheng, Jeff Abbott, Liying Liu, Mee Y Bartee, Maureen Long3 Jennifer Davids, Jennifer Williams, Heinrich Feldmann, Colin Macaulay, Grant McFadden, Robert Thoburn, David A. Lomas, Francis G. Spinale, Herbert W. Virgin, and Alexandra Lucas. Poxvirus-derived Serpin Prolongs Survival as a Unique Therapeutic Approach in Unrelated Lethal Mouse Viral Infections. Antimicrobial Agents and Chemotherapy 57(9): 4114-4127 (2013).

  4. De Matos, AL, McFadden, G and Esteves, PJ. Positive evolutionary selection on the RIG-I-like receptor genes in mammals. PLoS One 8(11): e81864 (2013).

  5. Ogbomo, H, Lun, X, Zhang, J, Zemp, FJ, Stack D, Rahman, MR, McFadden, G, Mody, CH and Forsyth, PA. Immunovirotherapy for brain tumors: Myxoma virus accelerates NK lysis of malignant gliomas in vitro and in vivo. PLoS One 8(6): e66825 (2013).

  6. Rahman, MM, Liu, J, Chan, W, Rothenberg, S and McFadden, G. Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication. Plos Pathogens 9:7 e1003465 (2013).

  7. Chan, WM, Rahman, MM and McFadden G. Oncolytic Myxoma Virus: The path to clinic. Vaccine 33: 4252-4258 (2013).

  8. Bartee, E and McFadden, G. Cytokine Synergy: An underappreciated contributor to innate anti-viral immunity. Cytokine 63: 237-240 (2013).

  9. Ana Lemos de Matos, Jia Liu , Grant McFadden and Pedro J. Esteves. Insights into the evolution, structure and function of SAMD9 and SAMD9-like genes in mammals. BMC Evolutionary Biology 13: 121 (doi: 10.1186/1471-2148-13-121) (2013).

  10. Zemp, FJ, Mckenzie, BA, Lun, X, Maxwell, L, Reilly, KM, McFadden, G, Yong, VW and Forsyth, PA. Resistance to oncolytic myxoma virus therapy in Nf1-/-/Trp-/- syngeneic mouse glioma models is independent of anti-viral type I interferon. PLoS One 8(6) e65801 (2013).

  11. Zemp, FJ, Lun, X, McKenzie, BA, Zhou, H, Maxwell, L, Sun B, Kelly, JJP, Stechishin, O, Luchman, A, Weiss, S, Cairncross, JG, Hamilton, MG, Rabinovich, Rahman, MR, Mohamed, MR, Smallwood, S, Senger, DL, Bell, J, McFadden, G and Forsyth, PA. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro-Oncology 15(7): 904-920 (2013).

  12. Chan, WM, Bartee, EC, Moreb, JS, Dower, K, Connor, JH and McFadden G. Myxoma and vaccinia viruses bind differentially to human leukocytes. J Virology 87: 4445-4460 (2013).

  13. Jeng, D, Ma, Z, Barrett, JW, McFadden, G, Loeb, JA and Essani, K. The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. J Virology 87: 3018-3026 (2013).

  14. Craig N. Jenne, Connie H. Y. Wong, Braedon McDonald, Franz J. Zemp, Masmudur M. Rahman, Peter A. Forsyth, Grant McFadden and Paul Kubes. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host & Microbe 13: 169-180 (2013).


  1. Doty, RA, Liu, J, McFadden, G, Roy, EJ and MacNeill, AL. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma. Oncolytic Virotherapy 1: 1-17 ( (2012).

  2. Liu, J, Rothenberg S and McFadden, G. The Poxvirus C7L Host range Superfamily: An old story newly told. Current Opinion in Virology 2: 764-772 (2012).

  3. Li, S, Tong, J, Rahman, MM, Shepherd, TG and McFadden, G. Oncolytic virotherapy for ovarian cancer. Oncolytic Virotherapy 1: 1-21 (  (2012).

  4. Bartee, E, Chan, WS, Moreb, JS, Cogle, CR, and McFadden, G. Selective purging of human multiple myeloma cells from autologous stem cell transplant grafts using oncolytic myxoma virus. Biology of Blood and Marrow Transplantation, 18(10): 1540-1551 (2012).

  5. Bartee, E, Meachem, A, Wise, E, Cogle, C and McFadden, G. Virotherapy using myxoma virus prevents lethal graft-vs-host disease following xeno-transplantation with primary human hemapoietic stem cells. PLoS One 7(8): e43298 (2012).

  6. Wennier, S, Liu, J and McFadden, G.  Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy.  Cur Pharm. Biotechnology 13(9): 1817-1833 (2012).

  7. Cao, H, Dai, P, Wang, W, Li, H, Yuan, J, Fang, CM, Pitha, PM, Liu, J, Condit, RC, McFadden, G, Merghoub, T, Houghton, AN, Young, JW, Shuman, S and Deng, L. Innate immune response of human plamacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. PLoS One 7(5): e36823. doi:10.1371/journal.pone.0036823 (2012).

  8. Liu, J, Wennier, S, Moussatche, N, Reinhard, M, Condit, R and McFadden, G. Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits. J Virology 86: 5371-5375 (2012).

  9. McFadden, G. Pathogens and People: Reflections from Haiti. PLoS Medicine Blogs (2012)

  10. Correa, RJM, Komar, M, Tong, JGK, Sivapragasam, M, Rahman, MR, McFadden, G, DiMattia, GE and Shepherd, TG. Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecologic Oncology 125: 441-450 (2012).

  11. Wennier, S., Liu, J., Li, S., Rahman, M.M., Mona, M. and McFadden, G. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Molecular Therapy 20 (4): 759-768 (2012).

  12. *Madlambayan, GJ, *Bartee, E, *Kim, M, Rahman, M, Meacham, A, Smallwood, S, Scott, EW, McFadden, G and Cogle, C.  Oncolytic virus tropism in vitro does not predict oncolytic efficacy in vivo: Oncolytic efficacy of myxoma virus for nonpermissive human myeloid leukemia. Leukemia Research 36: 619-624 (2012) (* denotes co-lead authors).

  13. Bais, S, Bartee, E, Rahman, M, McFadden, G and C Cogle. Oncolytic Virotherapy for hematological malignancies. Advances in Virology, Special issue on Oncolytic Viruses doi: 10.1155/2012/186512 (2012).


  1. Jeng, D, Rahman, MM, McFadden, G and Essani, K. Tumor Necrosis Factor Inhibitors from Poxviruses with an Emphasis on Tanapoxvirus-2L Protein. Recent Pat DNA Gene Seq 5: 97-103 (2011).

  2. McFadden, G and Simon, AE. Building bridges between plant and animal viruses. Current Opinion in Virology 1: 319-321 (2011).

  3. Rahman, M. M., and McFadden, G. Myxoma virus lacking the Pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple TLRs, which independently activate the inflammasome and NF-κB innate response pathways. J Virology 85: 12505-12517 (2011).

  4. Dai, P, Cao, H, Merghoub, T, Francesca, A, Wang, W, Parikh, T, Fang, C-M, Pitha, PM, Fitzgerald, KA, Rahman, MR, McFadden, G, Houghton, AN, Shuman, S and Deng, L. Myxoma virus induces type I IFN production in murine plasmacytoid dendritic cells via a TLR9/MyD88, IRF5/IRF7, and the type I IFN receptor-dependent pathway. J Virology 85: 10814-25 (2011).

  5. Spiesschaert, B, McFadden, G, Hermans, K, Nauwynck, H, Van de Walle, G.  The current status and future directions of myxoma virus, a master in immune evasion. Veterinary Research 42: 76-94 (2011).

  6. Chen, H, Zheng, D, Davids, J, Bartee, MY, Thoburn, R, Sobel, E, Moyer, R, McFadden, G and Lucas, A. Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymology 499: 301-329 (2011).

  7. Thomas, DL, Doty, R, Tosic, V, Liu, J, Kranz, DM, McFadden, G, MacNeill, A and Roy, E. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol. Immunother. 60: 1461-1472 (2011).

  8. Wennier, S, Li, S, and McFadden, G. Oncolytic virotherapy for pancreatic cancer. Expert Rev. Molecular Medicine 13: e18 (2011).

  9. Rahman, M and McFadden, G.  Modulation of NF-kB signaling by microbial pathogens. Nat. Rev. Micro. 9: 291-306 (2011).

  10. Liu, J, Wennier, S, Zhang, L, and McFadden, G.  M062 is a host range factor with essential role in viral replication and binds to SAMD9 during infection in human cells. J. Virology 85(7): 3270-3282 (2011).

  11. France, MR, Thomas, DL, McFadden, G, MacNeill, A and Roy, E.  Intraventricular Injection of Myxoma Virus Results in Transient Expression of Viral Protein in Mouse Brain Ependymal and Subventricular Cells. J. General Virology 92:195-199 (2011).


  1. Liu, J, Wennier, S, and McFadden, G.  The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.  Microbes and Infection 12:1144-1152 (2010).

  2. Tardif, J-C, L’Allier, PL, Gregoire, J, Ibrahim, R, McFadden, G, Kostuk, W, Knudtson, M, Labinaz, M, Waksman, R, Pepine, C, Macaulay, C, Guertin, M-C, Lucas, A.  A Randomized Controlled Trial of the Viral Serpin Serp-1 in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.  Circ. Cardiovasc. Interv. 3:543-548 (2010).

  3. Smallwood, SE, Rahman, MM, Smith, DW and McFadden, G.  Myxoma virus: Propagation, purification, quantification and storage.  Current Protocols in Microbiology (doi:10.1002/9780471729259.mc14a01s17) (2010).

  4. Barrett, JW and G. McFadden.  Tanapox virus.  In Molecular Detection of Human Viral Pathogens (Ed. Lui D.), pp. 1037-1044. Taylor and Francis Publishing (2010).

  5. Kim, M, Williamson, C, Bebb, G, Forsyth, PP, Lee, PWK, Lees-Miller, S, McFadden, G, and Johnston, RN. The cellular tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is regulated by common host tumor suppressor genes. Oncogene 29:3990-3996 (2010).

  6. Rahman, MM, Madlambayan, GJ, Cogle, CR, and McFadden, G.  Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with myxoma virus. Cytokine and Growth Factor Reviews 21:169-175 (2010).

  7. Dai, E, McIvor, D, Liu, L-Y, Sun, Y, Macaulay, C, King, E, Munuswamy-Ramanujam, G, Esko, JD, Charo, I, McFadden, G, and Lucas, A. Chemokine regulation of inflammatory cell invasion and transplant vasculopathy: analysis of glycosaminoglycan and receptor interactions.  PLOS One 5(5):e10510.doi:10.1371/journal.pone.0010510.

  8. Villa, NY, Bartee, E, Mohamed, MR, Rahman, MM, Barrett, JW and McFadden, G.  Myxoma and vaccinia virus exploit different mechanisms to enter and infect human cancer cells.  Virology 401:266-279 (2010).

  9. Früh, K, Finlay, B, McFadden, G.  On the road to systems biology of host-pathogen interactions.  Future Microbiology 5(2):131-133 (2010).

  10. Werden, SJ and McFadden, G.  Pharmacological manipulation of the Akt signaling pathway regulates myxoma virus replication in human cancer cells. J Virol 84(7):3287-3302 (2010).

  11. McFadden, G.  Killing a Killer: What next for Smallpox?  PLoS Pathogens 6(1):e1000727 (2010).

  12. Josiah, D, Zhu, D, Dreher, F, Olson, J, McFadden, G, and Caldas, H.  Adipose-derived Stem Cells as Therapeutic Delivery Vehicles of an Oncolytic Virus for Glioblastoma. Molecular Therapy 18(2):377-385 (2010).

  13. Lun, X, Alain, T, Zemp, F, Zhou, H, Rahman, M, Hamilton, M, McFadden, G, Bell, J, Senger, DL, Forsyth, PA.  Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin. Cancer Research 70(2):598-608 (2010).


  1. Van Vliet, K, Mohamed, MR, Zhang, L, Villa, N, Werden, S, Liu, J, McFadden, G. Poxvirus Proteomics. Micro. Mol. Biol. Reviews 73(4):730-749 (2009).

  2. Rahman, MM, Mohamed, MR, Kim, M, Smallwood, S, McFadden, G.  Co-regulation of NF-кB and inflammasome-mediated inflammatory responses by Myxoma virus pyrin domain-containing protein M013. PLoS Pathogens 5(10): e1000635 (doi:10.1371/journal.ppat.1000635) (2009).

  3. Werden, S, Lanchbury, J, Shattuck, D, Neff, C, Dufford, M, McFadden, G.  Myxoma virus M-T5 ankyrin-repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells. J. Virology 83:12068-83 (2009).

  4. Kim, M*, Madlambayan, G*, Rahman, M, Smallwood, S, Joseph, S, Meacham, A, Hosaka, K, Scott, EW, Cogle, C, McFadden, G.  Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. (*co-lead authors). Leukemia 23:2313-2317 (2009).

  5. Zhang, L, Villa, N, Rahman, MM, Smallwood, S, Shattuck, D, Neff, C, Dufford, M, Lanchbury, J, LaBaer, J, McFadden, G.  Analysis of Vaccinia Virus – Host Protein – Protein Interactions: Validations of Yeast Two-Hybrid Screenings. J. Proteome Research 8:4311-4318 (2009).

  6. Mohamed, MR, & McFadden, G. NFкB inhibitors: Strategies from poxviruses. Cell Cycle 8(19): 3125-3132 (2009).

  7. Zhang, L, Stanford, M, Liu, J, Barrett, C, Jiang, L, Barclay, NA, McFadden, G.  Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200). J. Virology 83(18):9602-9607 (2009).

  8. Mohamed, MR, Rahman, MM, Rice, A, Moyer, R, Werden, S, McFadden, G.  Cowpox virus expresses a novel ankyrin repeat NF-кB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis. J. Virology 83(18):9223-9236 (2009).

  9. Bartee, E, McFadden, G.  Human cancer cells have specifically lost the ability to induce the synergistic state caused by Tumor Necrosis Factor plus Interferon-β. Cytokine 47:199-205 (2009).

  10. Barrett, JW, Werden, SJ, Wang, F, Jimenez, J, Villeneuve, D, McFadden, G, and Dekaban, GA. Myxoma virus M130R is required for lethal myxomatosis in rabbits. Virus Research 144:258-265 (2009).

  11. Kerr, P, and McFadden, G. Leporipoxviruses In: Tidona, C., Darai, G. (Eds.) The Springer Index of Viruses, 2nd ed. Springer, New York, USA (2009).

  12. McFadden, G, Mohamed, MR, Rahman, MM, Bartee, E.  Cytokine determinants of viral tropism. Nature Reviews Immunology 9:645-655 (2009).

  13. Madhani, HD, Haldar, K, McFadden, G.  “Pearls”: A new type of open-access educational resource.  PLoS Pathogens 5(6): e1000499 (2009).

  14. Mohamed, M, Rahman, M, Lanchbury, J, Shattuch, D, Neff, C, Dufford, M, van Buuren, N, Fagan, K, Barry M, Smith, S, Damon, I, McFadden, G.  Proteomic screening of variola reveals a novel NF-кB inhibitor that is highly conserved among pathogenic orthopoxviruses. Proc. Nat. Acad. Sci. USA 106(22): 9045-9050 (2009).

  15. Enquist, LW, Beemon, KL, Caughey, BW, Dermody, TS, Diamond, MS, DiMaio, DC, Doms, RW, Ganem, DE, Greenberg, HB, Hahn, BH, Imperiale, MJ, Koup, RA, Lyles, DS, McFadden, G, Nelson, JA, Palese, PM, Perlman, S, Raab-Traub, N, Ross, SR, Sandri-Goldin, RM, Semler, BL, Sen, GC, Simon, A.  Virology in the 21st century.  J. Virology 83(11): 5296-5308 (2009).

  16. Liu, J, Weinnier, S, Reinhard, M, Roy, E, MacNeill, A, McFadden, G.  Myxoma virus expressing IL-15 fails to cause lethal myxomatosis in European rabbits. J. Virology 83: 5933-5938 (2009).

  17. Wang, F, Barret, JW, Ma, Y, Dekaban, GA, McFadden, G.  Induction of Alpha/Beta interferon by myxoma virus is selectively abrogated when primary murine embryo fibroblasts become immortalized. J. Virology 83(11): 5928-5932 (2009).

  18. Bartee, MY, Dai, E, Liu, L, Munuswamy-Ramanujam, G, Macaulay, C, McIvor, D, McFadden, G, Lucas, AR.  M-T7: Measuring chemokine-modulating activity.  Methods in Enzymology 460: 209-228 (2009).

  19. Wang, F, Barrett, J, Shao, Q, Gao, X, Dekaban, G and McFadden, G. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of Tyk2. Virology 387:136-146 (2009).

  20. Zhang, L, Villa, N, and McFadden, G. Interplay between poxviruses and the cellular ubiquitin/ubiquitin-like (Ub/Ubl) pathways. FEB Lett 583:607-614 (2009).

  21. Rahman, M, Jeng, D, Singh, R, Coughlin, J, Essani, K, McFadden, G.  Interaction of human TNF and β2-microglobulin with Tanapox virus-encoded TNF inhibitor, TPV-2L. Virology 386:462-468(2009).

  22. Bartee, E, Mohamed, MR, Lopez, C, Baker, H, and McFadden, G. Addition of TNF plus IFN-β induces a novel synergistic anti-viral state against poxviruses in primary human fibroblasts. J Virology 83(2):498-511 (2009).

  23. Rahman, MM, Lucas, AR, and McFadden, G. Viral TNF inhibitors as potential therapeutics. In: Pathogen-derived Immunomodulatory Molecules (Ed. P. Fallon) Landes Bioscience (2009). Chapter 5, pp. 64-77.


  1. Moussatché, N, Damaso, CR, and McFadden, G. When good vaccines go wild: Feral orthopoxvirus in the third world and beyond. J. Inf. Developing Countries 2(3):156-173 (2008).

  2. Bartee, E, Mohamed, MR, and McFadden G. Tumor necrosis factor and interferon: Cytokines in harmony.  Curr. Op. Micro. 11(4):378-383 (2008).

  3. Li, X, Schneider, H, Peters, A, Macaulay, C, King, E, Sun, Y, Liu, L, Dai, E, Davids, JA, McFadden, G, Lucas, A.  Heparin alters viral serp-1, anti-thrombolytic activity to anti-thrombotic activity. Open Biochem. J. 2:6-15 (2008).

  4. Wang, F, Gao, X, Irvine, T, Barrett, JW, Shao, Q, Cao, J, and McFadden, G. R1G-I-mediated induction of tumor necrosis factor is essential for human cellular innate restriction to myxoma virus. PLoS Pathogens  4:e1000099 (2008).

  5. Adams, MM, van Leeuwen, BH, McFadden, G, and Kerr, PJ. Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells. Vet Research 39:60 DOI: 10.1051/vetres:2008037 (2008)

  6. Lucas, A, Liu, L, Dai, E, Bot, Il, Viswanathan, K, Munuswamy-Ramunujam, G, Davids, JA, Bartee, MY, Richardson, J, Christov, A, Wang, H, Macaulay, C, Poznansky, M, Zhong, R, Miller, L, Biessen, E, Richardson, M, Moyer, R, Hatton, M, Lomas, DA, and McFadden G. The Serpin Saga; Development of a New Class of Virus Derived Anti-Inflammatory Protein Immunotherapeutics. In: Pathogen-derived Immunomodulatory Molecules (Ed. P. Fallon)

  7. Haldar, K., G. McFadden, and J. A. Young. "Change in the editorial leadership of PLoS Pathogens." PLoS.Pathogens 4(9): e1000167. doi:10.1371/journal.ppat.1000167 (2008).

  8. Woo, Y, Stanford, MM, Galanis, C, Chun, YS, Fong, Y, and McFadden, G. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann. Surg. Oncology 15(8):2329-2335 (2008).

  9. Barrett, JW and McFadden, G. Origin and Evolution of Poxviruses. In: Origin and Evolution of Viruses, 2nd Edition. (Ed. E. Domingo, C.R. Parrish, and J. Holland). pp. 431-446 Oxford: Elsevier Publishing (2008).

  10. Werden, SJ, Rahman, MM, and McFadden, G. Poxvirus host range genes. Adv. Virus Research 71:135-171 (2008).

  11. Barrett JW and McFadden G.  Yatapoxviruses.  In Encyclopedia of Virology Third Edition (Eds. BWJ Mahy and MHV Van Regenmortel), pp. 461-465. Oxford: Elsevier (2008).

  12. McFadden, G. Leporipoxviruses and Suipoxviruses.  In Encyclopedia of Virology Third Edition (Eds. BWJ Mahy and MHV Van Regenmortel), pp. 225-230.  Oxford: Elsevier (2008).

  13. Su, J, Willert, C, Comanita, L, Peters, A, Gilbert, P-A, Strathdee, C, O’Connell, P, McFadden, G, and Dekaban GA. Anti-apoptotic molecule M11L enhances CD8+ T cell responses to HIV-1 envelope protein in a prime-boost vaccine regimen. Virology 375:48-58 (2008).

  14. Werden, SJ, and McFadden, G. The role of cell signaling in poxvirus tropism: The case of the M T5 host range protein of myxoma virus. BBA-Proteins and Proteomics. 1784:228-237 (2008).

  15. Wu, Y, Lun, X, Zhou, H, Wang, L, Sun, B, Bell, JC, Barrett, JW, McFadden, G, Biegel, JA, Senger, DL, and Forsyth, PA. Oncolytic efficacy of recombinant vesicular stomatitis virus (VSVΔM51) and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res. 14(4):1218-1227 (2008).

  16. Stanford, MM, Breitbach, CJ, Bell, JC, and McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: Friends or foes? Curr. Op. Molec. Therapeutics 10(1):32-37 (2008).

  17. Stanford, MM, Shaban, M, Barrett JW, Gilbert, PA, Bondy-Denomy J, Mackenzie L, Graham KC, Chambers AF, and McFadden, G. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo Molecular Therapy 16:52-59 (2008).

  18. Nazarian, SH, Rahman, MM, Werden, SJ, Villeneuve, D, Meng, X, Brunetti, C, Valeriano, C, Wong, C, Singh, R, Barrett, JW, Xiang, Y, and McFadden, G. Yaba monkey tumor virus encodes a functional inhibitor of IL-18. J. Virology 82(1):522-528 (2008).


  1. Stanford, MM, and McFadden, G. Myxoma virus and oncolytic virotherapy: A new biological weapon in the war against cancer. Exp. Op. Bio. Ther.  7:1415-25 (2007).

  2. Barrett, JW, Alston, LR, Wang, F, Stanford, MM, Gilbert, P-A, Gao, X, Jimenez, J, Villeneuve, D, Forsyth, P and McFadden, G. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J NeuroVirology 13(6):549-560 (2007).

  3. Jiang, J, Arp, J, Kubelik, D, Zassoko, R, Liu, W, Wise, Y, Macaulay, C, Garcia, B, McFadden, G, Lucas, AR, and Wang, H. Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibityor-1 (Serp-1) treatment. Transplantation 84:1158-1167 (2007).

  4. Johnston JB, Rahman MM, and McFadden G. Strategies that modulate inflammasomes – insights from host-pathogen interactions. Sem in Immunopathology 29(3):261-274 (2007).

  5. Stanford, MM, Barrett, JW, Gilbert, P-A, Bankert, R, and McFadden, G.  Myxoma virus expressing human IL-12 does not induce myxomatosis in European rabbits. J Virology 81(22):12704-12708 (2007).

  6. Nazarian, SH, Barrett, JW, Stanford, MM, Johnston, SB, Essani, K, and McFadden, G. Tropism of Tanapox virus infection of primary human cells. Virology 368:32-40 (2007).

  7. Lun, XQ, Zhou, H, Alain, T, Sun, B, Wang, L, Barrett, JW, Stanford, MM, McFadden, G, Bell, J, Senger, DL, and Forsyth PA. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Research 67(18):8818-8827 (2007).

  8. Nazarian, SH, Barrett, JW, Frace, AM, Olsen-Rasmussen, M, Khristova, M, Shaban, M, Neering, S, Li, Y, Damon, IK, Esposito, JJ, Essani K, and McFadden, G. Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus. Virus Research 129:11-25 (2007).

  9. Rahman, MM, and McFadden G. BAFfled by Poxviruses? Cell  Host & Microbe 1:159-160 (2007).

  10. Douglas, AE, Corbett, KD, Berger, JM, McFadden, G, and Handel, TM.  Structure of M11L:  A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2.  Protein Sci. 16:695-703 (2007).

  11. Barrett, JW, Chang, CS, Wang, G, Werden, SJ, Shao Z, Barrett, C, Gao, X, Belsito, TA, Villeneuve, D, and McFadden, G. Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. Virology 361:123-132 (2007).

  12. Stanford, MM, McFadden, G., Karupiah, G, and Chaudhri, G.  Immunopathology of poxvirus infections: forecasting the impending storm.  Imm. Cell. Biol.  85(2):93-102 (2007).

  13. Werden, S, Barrett, JW, Wang, G, Stanford, M, and McFadden, G. M-T5, the ankyrin repeat, host range protein of myxoma virus activates Akt and can be functionally replaced by PIKE-A. Journal of Virology 81:2340-2348 (2007).

  14. Stanford M, Werden S, and McFadden G. Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Veterinary Research. 38:299-318 (2007).

  15. Stanford, MM, Barrett, JW, Nazarian, SH, Werden, S and McFadden, G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells, Journal of Virology 81:1251-1260 (2007).

  16. Barrett, JW, Sypula, J, Wang, F, Alston, L, Shao, Z, Gao, X, Irvine, TS, and McFadden, G. M135R is a novel cell surface virulence factor of myxoma virus. J. Virology 81:106-114 (2007).

  17. Nazarian, SH. and McFadden, G.  “Immunomodulation by Poxviruses” In Advances in Infectious Diseases (Ed. Andrew Mercer) Birkhäuser Publishing. Basel Switzerland, pp 273-296 (2007).

  18. Barrett, JW and McFadden, G. “The Leporipoxviruses” In Advances in Infectious Diseases (Ed. Andrew Mercer) Birkhäuser Publishing, Basel Switzerland, pp. 183-201 (2007).


  1. Gilbert, PA and McFadden, G.  Poxvirus cancer therapy. Rec. Pat. Anti-Infective Drug Dis. 1:309-321 (2006).

  2. Sedger, LM, Osvath, SR, Xu, X, Li, G, Chan, F.K-M, Barrett, J. and McFadden, G. Poxviral Tumour Necrosis Factor Receptor (RNFR)-like T2 proteins contain a conserved pre-ligand assembly domain (PLAD) that inhibits cellular TNF-R1 induced cell death J. Virology 80(18):9300-9309 (2006).

  3. Rahman MM, Barrett JW, Brouckaert P and McFadden G. Variation in ligand binding specificities of a novel class of poxvirus-encoded TNF-binding protein, (2006) J Biol. Chem. 281:22517-22526 (2006).

  4. Barrett JW, Sun Y, Nazarian SH, Belsito T and McFadden G. Optimization of codon usage of poxvirus genes allows for improved transient expression of mammalian cells Virus Genes 33:15-26 (2006).

  5. Dai E, Viswanathan K, Sun YM, Li X, Liu L, Togonu-Bickersteth B, Richardson, J, Macaulay C, Nash P, Turner P, Nazarian SH, Moyer R, McFadden G and Lucas AR.  Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses J Biol. Chem. 281: 8041-8050 (2006).

  6. Wang G*, Barrett JW*, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ and McFadden G (*denotes co-lead authorship) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. PNAS 103(12) 4640-4645 (2006).

  7. Bedard, ELR, J Jiang, J Arp, H Wang, H Guan, L Liu, LN Parry, P Kim, B Garcia, X Li, C Macauley, G McFadden, A Lucas and R Zhong. Prevention of chronic renal allograft rejection by SERP-1 protein. Transplantation (2006) 81:908-914.

  8. Finlay B and McFadden G. Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens Cell 124:767-782 (2006).

  9. Rahman, MM and McFadden, G Modulation of tumor necrosis factor (TNF) by microbial pathogens PLoS Pathogens 2:66-77 (2006).

  10. Su J*, Wang G*, Barrett JW, Irvine TS, Gao X and McFadden G. Myxoma virus M11L blocks apoptosis through inhibition of the conformational activaton of Bax at the mitochondria Journal of Virology 80(3): 1140-1151 (2006).

  11. Lucas, A, McIvor, D. and McFadden, G. Virus-encoded chemokine modulators as novel anti-inflammatory reagents.  In “Progress in Inflammatory Research” (Eds. B. Moser, GL. Letts and K. Neote). Birkhauser Publishing, Basel, Switzerland, Vol. 1: pp. 165-182 (2006).

  12. Nazarian, Steven H and McFadden G. Immune evasion by poxviruses.  Future Virology 1(1):123-132 (2006).


  1. Johnston, JB and McFadden, G.  Immunomodulation by poxviruses: insights into virus-host interactions by selectively deleting poxvirus genes.  In “Modulation of Host gene expression of innate immunity by viruses.” (Ed. P. Palese). Kluwer Plenum Press, Ch. 8, pp. 163-186 (2005).

  2. Gao, M, N Bruffato, T Chen, LL Murley, R Thalakada, M Domagala, B Beattie, D Mamelak, V Athanasopoulos, D Johnson, G McFadden, C Burks and L Frappier.  Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system. Journal of Proteome Research 4:2225-2235 (2005).

  3. Gilbert, Philippe-Alexandre, Lacrimioara Comanita, John Barrett, Andrew Peters, Marta Szabat, Grant McFadden, Gregory A. Dekaban. 2005. Current status for high titre poxvirus stocks preparation in CEF under serum-free medium conditions: Implication for vaccine development. Cytotechnology 18:79-88 (2005).

  4. Johnston, JB J Barrett, SH Nazarian, M Goodwin, D Ricciuto, G Wang and G McFadden. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection Immunity 23:587-598 (2005).

  5. Lun, Xueqing, Yang, Wenqing, Alain, Tommy, Shi, Zhong-Quiao, Muzik, Huong, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, Peter A. Forsyth.  Myxoma virus is a novel oncolytic virus with significant activity against experimental gliomas Cancer Research 65(21): 9982-9990 (2005).

  6. Johnston, JB, Wang, G. Barrett, JW, Nazarian, SH, Colvill, K, Moran, M and G. McFadden.  Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. Journal of Virology 79(16): 10750-10763 (2005).

  7. McFadden, G. Gleevec casts a pox on poxvirus. Nature Medicine, 11(7):711-712 (2005).

  8. Stanford, MM. and McFadden, G.  The ‘supervirus’?: Lessons from IL-4 expressing poxviruses. Trends in Immunology 26(8):339-345 (2005).

  9. Cameron, C, Barrett, JW, Mann, M, Lucas, Alexandra R, and McFadden G. Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the down-regulation of macrophage activation in vivo. Virology 337:55-67 (2005).

  10. Cameron, CM, Barrett, JW, Liu L, Lucas, AR and McFadden, G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. Journal of Virology 79(20):6052-6067 (2005).

  11. McFadden, G.  Poxvirus tropism Nature Reviews Microbiology 3:201-213 (2005).

  12. Johnston, JB, Nazarian, S, Natale, R and McFadden, G.  Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses Virology 332:235-248 (2005).

  13. Perez, DR, Nazarian, SH, McFadden, G and Gilmore, M.S.   Miscellaneous threats: Highly pathogenic avian influenza and novel bio-engineered organisms.   Ch 21 In “Biodefense: Principles and Pathogens” (Eds. M. Bronze and R.A. Greenfield). Horizon Scientific Press pp. 711-734 (2005).

  14. Nazarian, SH, McFadden, G and Huycke, M.M. Smallpox Ch 11 In “Biodefense: Principles and Pathogens” (Eds. M. Bronze and R.A. Greenfield).  Horizon Scientific Press pp. 279-312 (2005).


  1. Wang, F, Ma, Y, Barrett, JW, Gao, X, Loh, J, Barton, E, Virgin IV, HW and G. McFadden, Disruption of ERK-dependant type I interferon induction breaks myxoma virus species barrier. Nature Immunology 5:1266-1274 (2004).

  2. McFadden, G.  Smallpox: An ancient disease enters the modern era of virogenomics. Proc. Nat. Acad. Sci, USA 101:14994-14995 (2004).

  3. Lucas, A and G. McFadden.  Secreted immunomodulatory proteins as novel biotherapeutics.  J. Immunology 173:4765-4774 (2004).

  4. Johnston, JB and McFadden, G.  Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes.  Cellular Microbiology 6(8):695-705 (2004).

  5. Wang, G, Barrett, JW, Nazarian, S H, Everett, H, Gao, X, Bleackley, C, Colwill, K, Moran, MF and McFadden, G.  Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak J. Virology  78:7097-7111 (2004).

  6. Liu, L, Dai, E, Miller, L., Seet, B, Lalani, A, Macauley, C, Li, X, Virgin, HW, Bunce, C, Turner, P, Moyer, R, McFadden, G, and Lucas, A.  Viral chemokine binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 77(11):1652-1660 (2004).

  7. Seet, B and McFadden, G.  Interaction analysis of viral cytokine-binding proteins using surface plasmon resonance.  In “Methods in Molecular Biology” Vol. 269, Ed. S. Isaacs.  Humana Press 219-242 (2004).

  8. Sypula, J, Wang, F, Ma, Y, Bell, J and McFadden, G.  Myxoma virus tropism in human tumor cells.  Gene Therapy and Molecular Biology 8:103-114 (2004).


  1. Seet, BT, McCaughan, CA, Handel, TM, Mercer, A, McFadden, G and Fleming, SB  Analysis of an orf virus chemokine-binding protein: shifting ligand specificity among a family of poxvirus viroceptors. Proc. Nat. Acad. Sci. USA 100(25):15137-15142 (2003).

  2. Brunetti, CR, Amano, H, Ueda, Y, Qin, J, Miyamura, T, Suzuko, T, Li, S, Barrett, JW and McFadden, G.  The complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus Journal of Virology 77(24):13335-13347 (2003).

  3. Bedard, ELR, Kim, P, Jiang, J, Parry, N, Liu, Y, Wang, H, Garcia, B, Li, X, McFadden, G, Lucas, A and Zhong, R.  Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts Transplantation 76:249-252 (2003).

  4. Dai, E, Guan, H, Liu, L, Little, S, McFadden, G, Vaziri, S, Cao, H, Ivanova, IA, Bocksch, L and Lucas, A  Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury.  J. Biol. Chem. 278: 18563-18572 (2003).

  5. Johnston, J and McFadden G.  Poxviruses Immunomodulation Strategies: Current Perspectives J. Virology 77:6093-6100 (2003).

  6. Johnston, JB, Barrett, JW, Chang, W, Chung, C, Zeng, W, Masters, J, Mann, M, Wang, F, Cao, J, and McFadden, G.  Role of the serine-threonine kinase, PAK-1, in myxoma virus replication. J. Virology 77:10 5877-5888 (2003)

  7. Brunetti, C, Paulose-Murphy, M, Singh, R, Qin, J, Barrett, JW, Tardivel, A, Schneider, P, Essani, K, and McFadden, G.  A secreted high affinity inhibitor of human TNF from tanapox virus PNAS 100:4831-4836 (2003).

  8. Li, X, King, E, Macaulay, C, Lucas, A and McFadden, G. Three Activity-Based Assays for Serp-1 BioProcess International 1: 48-55 (2003).

  9. Seet, BT, Johnston, J, Brunetti, C, Barrett, J, Everett, H, Cameron, C, Sypula, J, Nazarian, S., Lucas, A and McFadden, G.  Poxviruses and immune evasion.  Ann. Rev. Immunol.  21: 377-423 (2003).

  10. McFadden, G.  Viroceptors: Virus-encoded receptors for cytokines and chemokines. In “Cytokines and Chemokines in Infectious Diseases Handbook,” (Eds. M. Kotb and T. Calandra). Humana Press pp. 285-299 (2003).

  11. Mansouri, M, Bartee, E, Gouveia, K, Nerenberg, BTH, Barrett, J, Thomas, L, Thomas, G, McFadden, G and Freu, K.  The PHD/LAP-domain protein M153R of myxoma virus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4 J. Virology 77:1427-1440 (2003).


  1. Johnson, DC and McFadden, G.  Viral Immune Evasion.  In “Immunology of Infectious Diseases”   (Eds. Stefan H. E. Kaufman, Alan Sher and Rafi Ahmed).  ASM Press Ch. 24 (2002).

  2. Chang, CS and McFadden, G.  Characterization of a pan-species reactive monoclonal antibody specific for a cell surface epitope which could serve as a marker for human monocytic and megakaryocytic differentiation.  Hybridoma and Hybridomics 21:445-456 (2002).

  3. Chang,.CS and McFadden, G.  Characterization of a monoclonal antibody specific for a novel primate cell surface with distinct biochemical properties on human erythroleukemia and myeloid cell lines. Hybridoma and Hybridomics 21:271-280 (2002).

  4. Moyer, RM and McFadden, G.   Virus-encoded caspase inhibitors.  In “Caspases---Their Role in Cell Death and Cell Survival” (Eds. M. Los and H. Walczak) Landes Bio Science Ch 6, pp. 105-122 (2002).

  5. Everett, H, Barry, M, Lee, SF, Frantz, C, Berthiaume, LG, McFadden, G.(*) and Bleackley, R.C.(*).  The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore (*denotes co-corresponding authors) J. Exp. Med. 196:1127-1139 (2002).

  6. Smith, GL and McFadden, G.  Smallpox:  Anything to declare?  Nature Reviews Immunology 2:521-527 (2002).

  7. Everett, H and McFadden, G.  Poxviruses and apoptosis: A time to die.  Curr. Op. Microbiol.  5(4): 395-402 (2002).

  8. Kerr, P and McFadden, G.  Immune responses to myxoma virus.  Viral Immunology 15:229-246 (2002).

  9. Seet, BT and McFadden, G.  Viral chemokine binding proteins.  J. Leuk. Biol. 72:24-34 (2002)

  10. Kerr, P. and McFadden, G.  Leporipoxviruses. In “The Springer Index of Viruses”. (2002).

  11. Cao, JX, Teoh, MCT, Moon, M, McFadden, G and Evans, D.  Leporipoxvirus CnZn superoxide dismutase hemologs inhibit cellular superoxide dismutase but are not essential for virus replication or virulence.  Virology 296:125-135 (2002).


  1. Masters, J, Uddin, S, Platonias, LC, Zeng, W, McFadden, G. and Fish, E.  Poxvirus infection rapidly activates tyrosine kinase signal transduction.  J. Biol. Chem. 276:48371-48375 (2001).

  2. Cao, J.-X and McFadden, G.  Characterization of the myxoma virus M118L protein: A novel essential poxvirus IMV-associated protein Virus Genes 23:303-313 (2001).

  3. Everett, H. and McFadden, G.  Viruses and apoptosis: meddling with mitochondria Virology 288:1-7 (2001).

  4. Seet, BT, Singh, R, Paavola, C, Lau, E, Handel TM and McFadden, G.  Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor PNAS 98(16): 9008-9011 (2001).

  5. Seet, BT, Barrett, J, Robichaud, J, Shilton, B., Singh, R, and McFadden, G.  Glycosaminoglycan-binding properties of the myxoma virus CC-chemokine inhibitor, M-T1 J. Biol. Chem. 276(32):30504-30513 (2001).

  6. O’Brien, WJ, Heimann, T, Tsao, L, Seet, BT, McFadden, G and Taylor, JL  Regulation of nitric oxide synthase 2 in rabbit corneal cells. Invest. Ophthalmol. Vis. Sci. 42(3): 713-719 (2001).

  7. Cao, J.-X. and McFadden, G.  Manipulation of the immune system virus: Myxoma virus model. Mod. Aspects Immunobiol. 1(5):179-181 (2001).

  8. Everett, H. and McFadden, G.  Viral proteins and the mitochondrial apoptotic checkpoint. Cyt. Growth Factor Rev. 12:181-188 (2001).

  9. Barrett, JW, Cao, J.-X, Hota-Mitchell, S, and McFadden, G.  Immunomodulatory proteins of myxoma virus. Semin. Immunol. 13:73-84 (2001).


  1. McFadden, G. and Moyer, R.  CC Chemokine of Molluscum Contagiosum Virus.  ibid (2000).

  2. McFadden, G. and Moyer, R.  Poxvirus Membranebound G Protein-coupled Receptor Homologs.  ibid (2000).

  3. McFadden, G. and Moyer, R.  Parapoxvirus (Orf Virus) Il-10 Homolog.  ibid (2000).

  4. McFadden, G. and Moyer, R.  Poxvirus Secreted Complement Control Proteins.  ibid (2000).

  5. McFadden, G. and Moyer, R.  Poxvirus Growth Factors Related to Epidermal Growth Factor.  ibid (2000).

  6. McFadden, G. and Moyer, R.  Poxvirus Vascular Endothelial Growth Factor (VEGF) Homologs of Orf Virus.  ibid (2000).

  7. McFadden, G. and Moyer, R.  Serp-1, a Secreted Poxviral Serpin  ibid (2000).

  8. McFadden, G. and Moyer, R.  Vaccinia Virus Semaphorin. ibid  (2000).

  9. McFadden, G. and Moyer, R.  Poxvirus IFN Receptor Homologs.  ibid (2000).

  10. McFadden, G. and Moyer, R.  Poxvirus IFN Receptor Homologs.  ibid (2000)

  11. McFadden, G. and Moyer, R.  Poxvirus IL-1 Receptor Homologs.  ibid (2000).

  12. McFadden, G. and Moyer, R.  Poxvirus Secreted Chemokine-binding Proteins.  ibid (2000).

  13. McFadden G. and Moyer R.  Poxvirus TNF Receptor Homologs. In “Cytokine Database”. (Eds. J.J. Oppenheim and M. Feldmann).  Academic Press (2000).

  14. Lucas, A., Dai, E., Liu, L., Guan, H., Nash, P., McFadden, G. and Miller, L.  Transplant vasculopathy: Viral anti-inflammatory serpin regulation of atherogenesis. J. Heart Lung Transplant. 19(11): 1029-1038 (2000).

  15. McFadden, G.  Virus “Star Wars.”  Science and Medicine 7(3): 38-47 (2000).

  16. Nash, P., McFadden, G. and Whitty, A.  Application of linear free energy relationships to the serpin-proteinase inhibition mechanism.  FEBS Letters 475(1):1-6 (2000).

  17. Christov, A., Dai, E., Drangova, M., Liu, L., Abela, G.S., Nash, P., McFadden, G. and Lucas, A.  Optical detection of triggered atherosclerotic plaque by fluorescence emission analysis.  Photochem. Photobiol. 72(2): 242-252 (2000).

  18. McFadden, G. and Murphy, P.M.  Host-related immunomodulators encoded by poxviruses and herpesviruses.  Curr. Opin. Microbiol. 3(4): 371-378 (2000).

  19. Xu, X., Nash, P. and McFadden, G.  Myxoma virus expresses a TNF receptor homolog with two distinct functions. Virus Genes 21:97-109 (2000).

  20. van Berkel, V., Barrett, J., Tiffany, H.L., Fremont, D.H., Murphy, P.M., McFadden, G., Speck, S.H. and Virgin IVth, H.W.  Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 74(15): 6741-6747 (2000).

  21. Liu, L., Lalani, A., Dai, E., Seet, B., Macaulay, C., Singh, R., Fan, L., McFadden, G. and Lucas, A.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury.  J. Clin. Invest. 105(11): 1613-1621 (2000).

  22. Everett, H., Barry, M., Lee, S.F., Sun, X., Graham, K., Stone, J., Bleackley, C. and McFadden, G.  M11L: A novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes. J. Exp. Med. 191(9): 1487-1498 (2000).

  23. Miller, L.W., Dai, E., Nash, P., Liu, L., Icton, C., Klironomous, D., Fan, L., Nation, P.N., Zhong, R., McFadden, G. and Lucas, A.  Inhibition of transplant vasculopathy in a rat aortic model after infusion of an anti-inflammatory viral serpin. Circulation 101:1598-1605 (2000).

  24. Barry, M. and McFadden, G.  Regulation of apoptosis by poxviruses. In “Effects of Microbes on the Immune System” (Eds. M.W. Cunningham and R.S. Fujinami). Lippincott Williams and Wilkins pp. 509-520 (2000).

  25. Lalani, A.S., Barrett, J. and McFadden G.  Modulating chemokines: More lessons from viruses.  Immunol. Today 21(2): 100-106 (2000).

  26. Nash, P., Barry, M., Seet, B.T., Veugelers, K., Hota, S., Heger, J., Hodgkinson, C., Graham, K., Jackson, R.J. and McFadden, G.  Post-translational modification of the myxoma virus anti-inflammatory serpin, SERP-1 by a virally encoded sialyltransferase.  Biochem. J. 347:375-382 (2000).

Before 2000

  1. Cameron*, C. Hota-Mitchell*, S., Chen, L., Barrett, J., Cao, J.-X., Macaulay, C., Willer, D., Evans, D. and McFadden, G.  The complete DNA sequence of myxoma virus. Virology 264:298-318 (1999). (* denotes co-authorship).

  2. Willer, D.O., McFadden, G. and Evans, D.H..  The complete genome sequence of Shope (rabbit) fibroma virus Virology 264:319-343 (1999).

  3. Christov, A., Dai, E., Liu, L., Miller, L.W., Nash, P., Lalani, A., McFadden, G., Nation, P.N., Tulip, J., and Lucas, A.  Detection of transplant vasculopathy in a rat aortic allograft model by fluorescence spectroscopic optical analysis. Lasers Surg Med. 24(5):346-359 (1999).

  4. Lalani, A.S., Masters, J., Zeng, W., Barrett, J., Pannu, R., Everett, H., Arendt, C.W. and McFadden, G.  Use of chemokine receptors by poxviruses. Science 286(5446):1968-1971 (1999).

  5. Lalani, A.S. and McFadden, G.  Evasion and exploitation of chemokines by viruses. Cyt. Growth Factor Rev. 10:219-233 (1999).

  6. Hnatiuk, S., Barry, M., Zeng, W., Liu, L., Lucas, A., Percy, D. and McFadden, G.  Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. Virology 263:290-306 (1999).

  7. Zuniga, M.C., Hong, W., Barry, M., and McFadden, G. Endosomal/lysosomal retention and degradation of major histocompatibility complex Class I molecules is induced by myxoma virus. Virology 261:180-192 (1999).

  8. Lucas, A. and McFadden, G.  Harvesting viral proteins.  Can. Med. Assoc. J. 16:1134 (1999).

  9. Lalani, A.S., Masters, J., Graham, K., Liu, L., Lucas, A. and McFadden, G.  Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis.  Virology 256:233-245 (1999).

  10. McFadden, G.  Poxviruses (Poxviridae): Leporipoxviruses and Suipoxviruses. In “Encyclopedia of Virology,” Second Edition, (Eds. R.G. Webster and A. Granoff). Academic Press pp. 1381-1388 (1999).

  11. Nash, P., Barrett, J., Cao, J.-X., Hota-Mitchell, S., Lalani, A.S., Everett, H., Xu, X.-M., Robichaud, J., Hnatiuk, S., Ainslie, C., Seet, B. and McFadden, G.  Immunomodulation by viruses: The myxoma virus story.  Immunol. Rev. 168:103-120 (1999).

  12. Lalani, A., Nash, P., Seet, B. and McFadden, G.  Interaction of DNA virus proteins with host cytokines. In “DNA Viruses: A Practical Approach”. (Ed. A. Cann), Practical Approach Series, Oxford University Press. pp. 177-208 (1999).

  13. Everett, H. and McFadden, G.  Apoptosis as an innate immune response to virus infection.

  14. Lalani, A.S., Ness, T.L., Singh, R., Harrison, J.K., Seet, B.T., Kelvin, D.J., McFadden, G. and Moyer, R.W., Functional comparisons among members of the poxvirus T1/35kDa family of soluble CC-chemokine inhibitor glycoproteins. Virology 250:173-184 (1998).

  15. Nash, P., Whitty, A., Handwerker, J., Macen, J. and McFadden, G. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1.  J. Biol. Chem. 273:20982-20991 (1998).

  16. Barry, M. and McFadden, G.  Apoptosis regulators from DNA viruses.  Curr. Opin. Immunol. 10:422-430 (1998).

  17. McFadden, G., Lalani, A., Everett, H., Nash, P. and Xu, X.  Virus-encoded receptors for cytokines and chemokines.  Semin. Cell Dev. Biol. 9:359-368 (1998).

  18. McFadden, G. and Barry, M.  How poxviruses oppose apoptosis.  Semin. Virol. 8:429-442 (1998).

  19. McFadden, G.  Viruses and the immune system: Lessons from HIV.  UWO Medical Journal 67:39-40 (1998).

  20. McFadden, G.  Even viruses can learn to cope with stress. Science 279:40-41 (1998).

  21. Barry, M. and McFadden, G.  Virus encoded cytokines and cytokines receptors.  Parasitology 115:S89-S100 (1998).

  22. Lalani, A. and McFadden, G.  Secreted poxvirus chemokine binding proteins.  J. Leuk. Biol. 62:570-576 (1997).

  23. Barry, M., Hnatiuk, S., Mossman, K., Lee, S.W., Boshkov, L. and McFadden, G. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained in the endoplasmic reticulum and is important for the productive infection of lymphocytes.  Virology 239:360-377 (1997).

  24. Graham, K., Lalani. A., Macen, J., Ness, T.L., Barry, M., Liu, L., Lucas, A., Clark-Lewis, I., Moyer, R. and McFadden, G. The T1/35kDa family of poxvirus secreted proteins bind chemokines and modulate with leukocyte influx into virus-infected tissues.  Virology 229:12-24 (1997).

  25. McFadden, G. and Kelvin, D. New strategies for chemokine inhibition and modulation: You take the high road and I’ll take the low road.  Biochem. Pharm. 54:1271-1280 (1997).

  26. Lalani, A., Graham, K., Mossman, K., Rajarathnam, K., Lewis, I.C., Kelvin, D. and McFadden, G. The purified myxoma virus gamma interferon receptor homolog, M-T7, interacts with the heparin-binding domains of chemokines.  J. Virol. 71:4356-4363 (1997).

  27. Mossman, K., Barry, M. and McFadden, G. Regulation of interferon- gene expression and extracellular ligand function by immunomodulatory viral proteins. In "Gamma Interferon: A Pleiotropic Cytokine with Antiviral Activity" (Ed. G. Karupiah), R.G. Landes, Austin pp. 175-188 (1997).

  28. Schreiber, M., Sedger, L. and McFadden, G. Distinct domains of M-T2, the myxoma virus TNF receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition.  J. Virol. 71:2171-2181 (1997).

  29. McFadden, G., Schreiber, M. and Sedger, L. Myxoma T2 protein as a model for poxvirus encoded TNF receptors homologs.  J. Neuroimmunology 72:119-126 (1997).

  30. Nash, P., Lucas, A. and McFadden, G. SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. In “Chemistry and Biology of Serpins” (Eds. F. Church, D. Cunningham, D. Ginsburg, M. Hoffman, S. Stone and D. Tollefsen). Advances in Experimental Medicine and Biology Series.  pp. 195-205 (1997).

  31. Barry, M. and McFadden, G. Virokines and Viroceptors.  In "Cytokines in Health and Disease, 2nd Ed." (Eds. J.S. Friedland and D. G. Remick). Dekker Press pp. 251-262 (1997).

  32. McFadden, G., Graham, K. and Barry, M.  New strategies of immune modulation by DNA viruses.  Transplantation Proc. 28:2085-2088 (1996).

  33. Sedger, L. and McFadden, G.  M-T2: A poxvirus TNF receptor homologue with dual activities.  Immunology and Cell Biol. 74:538-545 (1996).

  34. Schreiber, M. and McFadden, G. Mutational analysis of the ligand-binding domain of M-T2 protein, the TNF receptor homologue of myxoma virus.  J. Immunol. 157:4486-4495 (1996)

  35. Ellison, K.S., Peng, W. and McFadden, G. Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability.  J. Virol. 70:7965-7973 (1996).

  36. Schreiber, M., Rajarathnam, K. and McFadden, G. Myxoma virus T2 protein, a TNF-receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF but the dimer is a more potent TNF inhibitor.  J. Biol. Chem. 271:13333-13341 (1996).

  37. Nathanson, N. and McFadden, G. Viral virulence. In "Viral Pathogenesis" (Ed. N. Nathanson). Lippincott-Raven Press pp. 85-103 (1996).

  38. Mossman, K., Lee, S.F., Barry, M., Boshkov, L. and McFadden, G. Disruption of M-T5, a novel myxoma virus gene member of the poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits.  J. Virol. 70:4394-4410 (1996).

  39. Macen, J.L., Garner, R.S., Musy, P.Y., Brooks, M.A., Turner, P.C., Moyer, R.W., McFadden, G. and Bleackley, R.C. Differential inhibition of the Fas and granule-mediated cytolysis pathways by the orthopoxvirus crmA/SPI-2 and SPI-1 protein.  Proc. Natl. Acad. Sci., USA 93:9108-9113 (1996).

  40. Mossman, K., Nation, P., Macen, J., Garbutt, M., Lucas, A. and McFadden, G. Myxoma virus M-T7, a secreted homolog of the interferon- receptor, is a critical virulence factor for the development of myxomatosis in European rabbits.  Virology 215:17-30 (1996).

  41. Maksymowych, W.P., Nation, N., Nash, P., Macen, J., Lucas, A, McFadden, G. and Russell, A.S. Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor.  J. Rheum. 23:878-882 (1996).

  42. Macen, J.L., Graham, K., Lee, S.F., Schreiber, M., Boshkov, L. and McFadden, G. Expression of the myxoma virus TNF receptor homologue (T2) and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes.  Virology 218:232-237 (1996).

  43. Lucas, A., Liu, L., Macen, J., Nash, P., Dai, E., Stewart, M., Graham, K., Etches, W., Boshkov, L., Nation, P., Humen, D., Hobman, M.Z. and McFadden, G. A virus-encoded serine protease inhibitor, SERP-1, inhibits atherosclerotic plaque development following balloon angioplasty.  Circulation 94:2890-2900 (1996).

  44. McFadden, G. Getting to know you: Viruses meet CD40 ligand.  Nature Medicine (News and Views) 1:408-409 (1995).

  45. Barry, M., Lee, S.F., Boshkov, L. and McFadden, G. Myxoma virus induces extensive CD4 downregulation and dissociation of p56lck in infected rabbit CD4+ T lymphocytes. J. Virol. 69:5243-5251 (1995).

  46. Mossman, K., Buller, R.L., Upton, C. and McFadden, G. Species specificity of ectromelia virus and vaccinia virus interferon -binding proteins.  Virology 208:762-769 (1995).

  47. Mossman, K., Upton, C. and McFadden, G. The myxoma virus-soluble interferon- receptor homolog, M-T7, inhibits interferon- in a species specific manner.  J. Biol. Chem. 270:3031-3038 (1995).

  48. Mossman, K., Ostergaard, H., Upton, C., and McFadden. G.  Myxoma virus and Shope fibroma virus encode dual-specificity tyrosine/serine phosphatases which are essential for virus viability.  Virology 206:572-582 (1995).

  49. McFadden, G., Graham, K., Ellison, K., Barry, M., Macen, J., Schreiber, M., Mossman, K., Nash, P., Lalani, A. and Everett, H. Interruption of cytokine networks by poxviruses: Lessons from myxoma virus.  J. Leuk. Biol. 57:731-738 (1995).

  50. Mossman, K., Barry, M. and McFadden, G. Poxvirus-encoded homologues of the gamma-interferon receptor.  ("Viroceptors, virokines, and related mechanisms of immune modulation by DNA viruses." Ed. G. McFadden). R.G. Landes Co. pp. 41-54 (1995).

  51. McFadden, G., Graham, K. and Opgenorth, A. Poxvirus growth factors. In "Viroceptors, virokines, and related mechanisms of immune modulation by DNA viruses." (Ed. G. McFadden). R.G. Landes Co. pp. 1-15 (1995).

  52. Schreiber, M. and McFadden. G., The myxoma virus TNF receptor homologue (T2) inhibits TNF in a species-specific fashion.  Virology 204:692-705 (1994).

  53. McFadden, G. and K. Graham. Modulation of cytokine networks by poxviruses: The myxoma virus model.  Semin. Virol. 5:421-429 (1994).

  54. Upton, C., Schiff, L., Rice, S.A., Dowdeswell, T., Yang, X. and McFadden, G. A poxvirus protein with a RING finger motif binds zinc and localizes in virus factories.  J. Virol. 68:4186-4195 (1994).

  55. Upton, C. and McFadden, G. Detection of viral homologues of cellular -interferon receptors. In “Molecular Virology Techniques. Part A”. (Methods in Molecular Genetics. Vol 4). (Ed. K.W. Adolph). Academic Press, Inc. pp. 383-390 (1994).

  56. McFadden, G. DNA viruses that affect cytokine networks (Chapter 27). In “Human Cytokines: Their Role in Health and Disease”. (Eds. B.B. Aggarwal and R.K. Puri). Blackwell Press, pp. 403-422 (1994).

  57. Kane, K. and McFadden, G.  How DNA viruses perturb functional MHC expression to evade the immune response.  Adv. in Cancer Res. 63:117-209 (1994).

  58. McFadden, G.  Myxoma, rabbit fibroma, hare fibroma, squirrel fibroma and swinepox viruses.  Encyclopedia of Virology (Ed. R.G. Webster and A. Granoff).  Sanders Scientific Pub. pp. 1153-1160 (1994).

  59. Macen, J., Upton, C., Nation, N. and McFadden, G.  SERP-1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation.  Virology 195:348-363 (1993).

  60. Stuart, D., Upton, C., Higman, M.A., Niles, E.G. and McFadden, G. A poxvirus-encoded uracil DNA glycosylase is essential for virus viability.  J. Virol. 67:2503-2512 (1993).

  61. Upton, C., Stuart, D. and McFadden, G.  Identification of a poxvirus gene encoding a uracil DNA glycosylase.  Proc. Natl. Acad. Sci., USA 90:4518-4522 (1993).

  62. Opgenorth, A., Nation, N., Graham, K. and McFadden, G.  Transforming growth factor alpha, Shope fibroma growth factor and vaccinia growth factor can replace myxoma growth factor as a virulence gene in the induction of myxomatosis in rabbits.  Virology 192:701-709 (1993).

  63. Lomas, D.A., Evans, D.L., Upton, C., McFadden, G. and Carrell, R.W.,  Inhibition of plasmin, urokinase, tissue plasminogen activator and C1S by a myxoma virus serine proteinase inhibitor.  J. Biol. Chem. 268:516-521 (1993).

  64. Upton, C., Mossman, K., and McFadden, G.  Encoding of a homolog of the IFN- receptor by myxoma virus.  Science 258:1369-1372 (1992).

  65. Graham, K., Opgenorth, A., Upton, C. and McFadden, G.  Myxoma virus M11L ORF encodes a protein for which cell surface localization is critical for manifestation of viral virulence.  Virology 191:112-124 (1992).

  66. Opgenorth, A., Graham, K., Nation, N., Strayer, D. and McFadden, G.  Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor.  J. Virol. 66:4720-4731 (1992).

  67. Stuart, D., Ellison, K., Graham, K. and McFadden, G.  In vitro resolution of poxvirus replicative intermediates into linear minichromosomes with hairpin termini by a virally induced Holliday junction endonuclease.  J. Virol. 66:1551-1563 (1992).

  68. Massung, R., McFadden, G. and Moyer, R.W., Nucleotide sequence analysis of a unique near-terminal region of the tumorigenic poxvirus, Shope fibroma virus.  J. Gen. Virol. 73:2903-2911 (1992).

  69. Boshkov, L.K., Macen, J.L. and McFadden, G.  Virus-induced loss of class I major histocompatibility antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus.  J. Immunol. 148:881-887 (1992).

  70. Opgenorth, A., Strayer, D., Upton, C. and McFadden, G.  Deletion of the growth factor gene related to EGF and TGF reduces virulence of malignant rabbit fibroma virus. Virology 186:175-191 (1992).

  71. Upton, C., Stuart, D. and McFadden, G.  Identification and DNA sequence of the large subunit of the capping enzyme from Shope fibroma virus.  Virology 183:773-777 (1991).

  72. Upton, C., Macen, J., Schreiber, M. and McFadden, G.  Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence.  Virology 184:370-382 (1991).

  73. Smith, C.A., Davis, T., Wignall, Upton, C., McFadden G., Din, W.S. and Goodwin, R.G.  T2 open reading frame from Shope fibroma virus encodes a soluble form of the tumor necrosis factor receptor.  Bioch. Bioph. Res. Comm. 176:335-342 (1991).

  74. Stuart, D., Graham, K., Schrieber, M., Macaulay, C. and McFadden, G. The target DNA sequence for resolution of poxvirus replicative intermediates is an active late promoter.  J. Virol. 65:61-70 (1991).

  75. Upton, C., Macen, J.L., Wishart, D.S. and McFadden, G.  Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence.  Virology 179:618-631 (1990).

  76. Chang, W., Macaulay, C., Hu, S.L., Tam, J.P. and McFadden, G.  Tumorigenic poxviruses: Characterization of the expression of an EGF related gene in Shope fibroma virus.  Virology 179:926-930 (1990).

  77. Upton, C., Opgenorth, A., Tracktman, P. and McFadden, G.  Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene.  Virology 176:439-447 (1990).

  78. Sheng, M., McFadden, G. and Greenberg, M.E.  Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB. Neuron 4:571-582 (1990).

  79. Delange, A.M. and McFadden, G.  The role of telomeres in poxviral DNA replication.  Curr. Top. Microbiol. Imm.  Vol. 163.  (R. Moyer, Ed.) Springer Verlag, Berlin. pp. 71-92 (1990).

  80. Macaulay, C. and McFadden, G.  Tumorigenic poxviruses: Characterization of an early promoter from Shope fibroma virus.  Virology 172:237-246 (1989).

  81. McFadden, G.  Poxviruses of rabbits.  In  “Virus diseases in laboratory and captive animals”.  (Ed. G. Darai).  Martinus Nijhoff Publishing, Boston pp. 37-61 (1987).

  82. Lobe, C., Shaw, J., Fregeau, C., Duggan, B., Meier, M., Brewer, A., Upton, C., McFadden, G., Patient, R.K., Paetkau, V. and Bleackley, R.C.  Transcriptional regulation of two cytotoxic T lymphocyte-specific serine proteinase genes.  Nucleic Acids Res. 17: 5765-5779 (1989).

  83. Lobe, C., Upton, C., Duggan, G., Ehrman, N., Letellier, M., Bell, J., McFadden, G. and Bleackley, R.C.  Organization of two gene encoding cytotoxic T lymphocyte-specific serine proteases, CCPI and II.  Biochemistry 27:6941-6946 (1988).

  84. Upton, C., Macen, J.L., Maranchuk, R.A., Delange, A.M. and McFadden, G.  Tumorigenic poxviruses: Fine analysis of the recombination junctions in malignant rabbit fibroma virus, a recombinant between Shope fibroma virus and myxoma virus.  Virology 166:229-239 (1988).

  85. Sheng, M., Dougan, S.T., McFadden, G. and Greenberg, M.  Calcium and growth factor pathways of c-fos transcriptional activation require distinct upstream regulatory sequences.  Mol Cell. Biol. 8:2787-2796 (1988).

  86. Henning, W., Upton, C., Majumdar, R., McFadden, G. and Bridger, W.A.  Cloning and sequencing of the cytoplasmic precursor to the -subunit of rat liver succinyl-CoA synthetase.  Proc. Natl. Acad. Sci. U.S.A. 85:1432-1436 (1988).

  87. Dickie, P., Morgan, A.R. and McFadden, G.  Conformational isomerization of the Holliday junction associated with a cruciform during branch migration in supercoiled plasmid DNA.  J. Mol. Biol. 201:19-30 (1988).

  88. Evans, D., Stuart, D. and McFadden, G.  High levels of genetic recombination between cotransfected plasmid DNAs in poxvirus-infected mammalian cells.  J. Virol. 62:367-375 (1988).

  89. McFadden, G., Stuart, D., Upton, C., Dickie, P. and Morgan, A.R.  Replication and resolution of poxvirus telomeres.  In “Cancer Cells VI: Eukaryotic DNA Replication”.  (Eds. T.J. Kelly and B. Stillman).  Cold Spring Harbor Press pp. 77-85 (1988).

  90. Dickie, P., McFadden, G. and Morgan, A.R.  The site-specific cleavage of synthetic Holliday junction analogs and related branched DNA structures by bacteriophage T7 endonuclease 1.  J. Biol. Chem. 262:14826-14836 (1987).

  91. Upton, C., Delange, A.M. and McFadden, G.  Tumorigenic poxviruses: Genomic organization and DNA sequence of the terminal inverted repeats of Shope fibroma virus.  Virology 160:20-30 (1987).

  92. Delange, P., McFadden, G.  Efficient resolution of replicated poxvirus telomeres to native hairpin structures requires two inverted symmetrical copies of a core target DNA sequence.  J. Virol. 61:1957-1963 (1987).

  93. Dickie, P., Morgan, A.R. and McFadden, G.  Cruciform extrusion in plasmids bearing the replicative intermediate configuration of a poxvirus telomere.  J. Mol. Biol. 196:541-558 (1987).

  94. Upton, C., Macen, J. and McFadden, G.  Mapping and sequencing of a gene from myxoma virus that is related to those encoding epidermal growth factor and transforming growth factor alpha.  J. Virol. 61:1271-1275 (1987).

  95. Macaulay, C., Upton, C. and McFadden, G.  Tumorigenic poxviruses: Transcriptional mapping of the terminal inverted repeats of Shope Fibroma Virus.  Virology 158:381-393 (1987).

  96. Chang, W., Upton, C., Hu, S.-L., Purchio, A.F. and McFadden, G.  The genome of Shope Fibroma Virus, a tumorigenic poxvirus, contains a growth factor gene with sequence similarity to those encoding epidermal growth factor and transforming growth factor alpha.  Mol. Cell. Biol. 7:535-540 (1987).

  97. Upton, C. and McFadden, G.  Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus.  J. Virology 60:920-927 (1986).

  98. Upton, C., Carrell, R.W. and McFadden, G.  A novel member of the serpin superfamily is encoded on a circular plasmid-like DNA species isolated from rabbit cells.  FEBS Lett. 207:115-120 (1986).

  99. Delange, A.M., Reddy, M., Scraba, D., Upton, C. and McFadden, G.  Replication and resolution of cloned poxvirus telomeres in vivo generates linear minichromosomes with intact viral hairpin termini.  J. Virology 59:249-259 (1986).

  100. Upton, C. and McFadden, G.  Tumorigenic poxviruses: Analysis of viral DNA sequences implicated in the tumorigenic of Shope fibroma virus and malignant rabbit virus.  Virology 152:308-321 (1986).

  101. Delange, A.M. and McFadden, G.  Sequence-nonspecific replication of transfected plasmid DNA in poxvirus-infected cells.  Proc. Natl. Acad. Sci. U.S.A. 83:614-618 (1986).

  102. Upton, C. and McFadden, G.  DNA sequence homology between the terminal inverted repeats of Shope fibroma virus and an endogenous cellular plasmid species.  Mol. Cell. Biol. 6:265-276 (1986).

  103. Block, W., Upton, C. and McFadden, G.  Tumorigenic Poxviruses: Genomic organization of malignant rabbit virus, a recombinant between Shope fibroma virus and myxoma virus.  Virology 140:113-124 (1985).

  104. Delange, A.M., Macaulay, C., Block, W., Mueller, T. and McFadden, G.  Tumorigenic poxviruses: Construction of the composite physical map of the Shope Fibroma Virus Genome.  J. Virol. 50:408-416 (1984).

  105. Delange, A.M., Futcher, B., Morgan, A.R. and McFadden, G.  Cloning of the vaccinia virus telomeres in a yeast plasmid vector.  Gene 27:13-21 (1984).

  106. Wills, A., Delange, A.M., Gregson, C., Macaulay, C. and McFadden, G.  Physical characterization and molecular cloning of the Shope Fibroma virus DNA genome.  Virology 130:403-414 (1983).

  107. McFadden, G. and Morgan, A.R.  DNA cruciform structures: Implications for telomere replication in eukaryotes and instability of long palindromic DNA sequences in prokaryotes.  J. Theor. Biol. 97:343-349 (1982).

  108. McFadden, G. and Dales, S.  Organization and replication of poxvirus DNA.  “Organization and replication of viral DNA”. (Ed. A.S. Kaplan). CRC Press pp. 173-190 (1982).

  109. McFadden, G. and Dales, S.  Biogenesis of Poxvirus: Preliminary characterization of conditional lethal mutants of vaccinia virus defective in DNA synthesis.  Virology 103:68-79 (1980).

  110. Schumperli, D., Wyler, R., McFadden, G. and Dales, S.  Location of a new endonuclease restriction site associated with a temperature sensitive mutation of vaccinia virus.  Virology 101:281-285 (1980).

  111. McFadden, G., Essani, K. and Dales, S.  A new endonuclease restriction site which is at the locus of a ts mutation in vaccinia virus is associated with true and pseudo-reversion.  Virology 101:277-290 (1980).

  112. McFadden, G. and Dales, S.  Biogenesis of Poxvirus: Mirror image deletions in vaccinia virus DNA. Cell 18:101-108 (1979).

  113. Silver, M., McFadden, G., Wilson, S. and Dales, S.  Biogenesis of Poxvirus: Role of the DNA-dependent RNA polymerase II of the host during expression of late functions.  Proc. Natl. Acad. Sci. U.S.A. 76:4122-4125 (1979).

  114. McFadden, G., Pace, W.E., Purres, J. and Dales, S.  Biogenesis of Poxvirus: Transitory expression of Molluscum contagiosum early functions.  Virology 94:297-313 (1979).

  115. Dales, S., Milanovitch, V., Pogo, B.G.T., Wientraub, S.B., Huima, T., Wilton, S. and McFadden, G.  Biogenesis of vaccinia: Isolation of conditional lethal mutants and EM characterization of their phenotypically expressed defects.  Virology 84:403-428 (1978).

  116. McFadden, G. and Denhardt, D.T.  Contrasting effects of 2', 3'-dideoxyadenine on 2 steps in the replication of ΦX174 DNA in Escherichia coli.  Virology 76:870-875 (1977).

  117. Denhardt, D.T., Eisenberg, S., Harbers, B., Lanes, H.E.D. and McFadden, G.  Replication of ΦX174 in Escherichia coli: Structure of the replicating intermediate and the effect of mutations in the host lig and rep genes.  DNA Synthesis and Its Regulation, eds. M. Goulian, P. Hanawalt and C.F. Fox.  Academic Press (1975).

  118. McFadden, G. and Denhardt, D.T.  Mechanism of replication of ΦX174single-stranded DNA. IX. Requirement for the E. coli DnaG protein.  J. Virol. 14:1070-1075 (1974).

  119. McFadden, G. and Denhardt, D.T.  The mechanism of replication of ΦX174single stranded DNA.  IX. Discontinuous synthesis in an E. coli strain with a temperature-sensitive ligase. J. Mol. Biol. 99:125-142 (1974).

  120. Denhardt, D.T., Iwaya, M., McFadden, G. and Schochetman, G.  The mechanism of replication of ΦX174 single stranded DNA.  VI.  Requirements for ribonucleoside triphosphates and DNA Polymerase III.  Can. J. Biochem. 51:1588-1597 (1973).